Loading…
RLMD
Relmada Therapeutics Inc
NASDAQ· Healthcare· Biotechnology
$4.33-4.20%
Key metrics
- Market cap
- $461.88M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.4x
- Dividend yield
- —
- EPS
- -$0.91
- ROE
- -25.63%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $8.00
- 52-week low
- $1.06
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
- 17
- Coral Gables, United States
Company description provided by Yahoo Finance.